Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura

Next Previous
Trial Profile

An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 31 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary) ; Methylprednisolone; Methylprednisolone; Prednisolone; Prednisolone; Rituximab
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Sponsors Sanofi

Most Recent Events

  • 12 Dec 2023 Results(n=22) presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 01 Mar 2023 Results assessing the efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenia purpura, published in the International Journal of Hematology.
  • 14 Dec 2021 Results assessing the efficacy and safety of caplacizumab in Japanese patients with iTTP presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top